HIGH SCHOOL EDITION
Journal of Student Research
Volume 12 Issue 3 (2023)

Type 2 Diabetes: Molecular Mechanism, Understanding and Prevention

Krish Pancholi[1], Jothsna Kethar[#] and Rajagopal Appavu[#]

[1]Northville High School
[#]Advisor

ABSTRACT

Diabetes is an international health issue due to its increasing prevalence and catastrophic effects on individuals and society. This research examines preventative measures, types, and consequences to attempt to provide a complete understanding of diabetes. The incidence of diabetes has increased for many causes, including dietary changes, sedentary lifestyles, and an aging population. Additionally, socioeconomic factors that affect health, like poverty and inequality, which are more common in underprivileged areas, increase the burden of diabetes. In type 1 diabetes, an autoimmune disorder, the pancreatic beta cells are damaged, resulting in inadequate insulin production. Contrarily, insulin resistance, in which the body's cells cease reacting to insulin, characterizes type 2 diabetes. The main objectives of Type 1 diabetes preventive programs are to maintain a healthy lifestyle and to reduce exposure to environmental variables. The treatment of Type 2 diabetes involves both medication control and dietary and activity modifications. The pathogenesis of both types of diabetes includes complex interactions between heredity and environment, which result in aberrant insulin secretion and action pathways. In this research paper, the causes of Type 1 and Type 2 diabetes will be analyzed along with potential preventative measures to minimize the severity of the illness.



Introduction

Millions of people worldwide have diabetes, which significantly impacts each person, their family, and society as a whole. It is one of the leading causes of mortality, disability, and healthcare expenses, and it can lead to significant problems such as cardiovascular disease, renal disease, blindness, and nerve damage. Additionally, the prevalence of diabetes is rising internationally, emphasizing the need for efficient management and preventative techniques. Several variables, including dietary changes, sedentary lifestyles, and an aging population, are to blame for this rise in prevalence. The burden of diabetes is also influenced by socioeconomic determinants of health, including poverty and inequality, which disproportionately impact vulnerable people. This study attempts to define diabetes, examine the condition's effects on daily life, and place it in a wider perspective to offer a thorough picture of the significance of diabetes. An autoimmune disease known as type 1 diabetes is characterized by the death of pancreatic beta cells, which prevents the organ from producing insulin. A metabolic illness known as Type 2 diabetes, on the other hand, is characterized by insulin resistance, in which the body's cells stop responding to insulin. Keeping a healthy lifestyle and limiting exposure to environmental factors are critical components of Type 1 diabetes prevention.

In contrast, Type 2 diabetes prevention calls for dietary and activity changes and medication administration. The complex interplay between hereditary and environmental variables underlies the molecular processes underlying the pathophysiology of Type 1 and Type 2 diabetes, resulting in malfunction in insulin production and action pathways. We will discuss the root causes of both type one and type two diabetes in this study paper, as well as possible preventative measures to lower the prevalence of the condition.



Understanding Type 1 Diabetes

Type 1 diabetes mellitus is a chronic disease that primarily affects younger people and is brought on by the destruction of the pancreatic beta cells, which results in inadequate insulin synthesis in the body. This disorder must be controlled with daily insulin injections, blood glucose testing, dietary changes, and lifestyle modifications. Although this course of therapy is complicated, time-consuming, and expensive, it is essential for avoiding diabetic consequences, including blindness, renal disease, neuropathy, and cardiovascular issues. But following this strenuous treatment plan can affect a person's social, emotional, and financial well-being, eventually lowering their quality of life. Managing type 1 diabetes mellitus may be extremely difficult for adolescents and young adults, and university students are especially at risk because of the increased responsibilities and pressures of student life. Social variables, including peer pressure, alcoholism, smoking, drug misuse, dietary restrictions, and eating disorders, are some of the barriers found in studies. Academic obstacles, including inconsistent schedules, a lack of free time, and money problems, can also make it difficult to manage diabetes properly. The management of diabetes in this group is further complicated by emotional and psychological obstacles such as stress, a lack of social support, a loss of parental participation, denial, rebellion, and feelings of social isolation.



Above is the prevalence ratio of the different types of diabetes and the percentage of the population with these specific diseases.

Type 1 Diabetes Diagnosis

Diabetes can be identified using several factors, including increased glycated hemoglobin (HbA1c) values, elevated random blood glucose levels, symptoms, and aberrant findings from an oral glucose tolerance test. A diagnosis of diabetes requires the presence of abnormal glycemia on two separate occasions. Although fasting or stimulated blood

glucose measures are more sensitive for diagnosis in people with type 1 diabetes because their dysglycemia can increase quickly, HbA1c readings above 48 mmol/mol (6.5%) can also suggest diabetes. Children with type 1 diabetes frequently have symptoms including weight loss, excessive thirst (polydipsia), and increased urine (polyuria). About one-third of patients may have diabetic ketoacidosis. Adults with type 1 diabetes, however, may not exhibit these typical symptoms, which might result in a wrong diagnosis. Up to 50% of instances of type 1 diabetes, formerly known as juvenile-onset diabetes, develop in adults. Type 1 diabetes can strike anybody at any age. Type 1 diabetes in adults may first be mistaken for type 2 diabetes. In addition, there are a few uncommon occurrences of monogenic diabetes in youngsters, and type 2 diabetes is also becoming more prevalent in teenagers, especially among non-Whites. No single clinical feature can unambiguously distinguish type 1 diabetes from other subtypes at diagnosis, even though low C-peptide concentration can indicate severe endogenous insulin deficiency and help with classification and treatment in diabetes cases assessed more than three years after clinical diagnosis. The classification process depends on identifying additional type 1 diabetes risk factors, clinical characteristics (such as age at diagnosis and body mass index), and biomarkers (like pancreatic autoantibodies). More than 90% of those who receive a type 1 diabetes diagnosis for the first time have antibodies that can be detected against particular beta cells proteins such as insulin, glutamate decarboxylase, islet antigen 2, zinc transporter 8, and tetraspanin-7. The earliest production of autoantibodies often occurs before the age of two, according to studies on those with a high hereditary risk of developing diabetes. Even while the majority of persons with a single autoantibody do not advance to clinical type 1 diabetes, children who have two or more autoantibodies have an 84% increased chance of acquiring the disease by the time they are 18. The stages of type 1 diabetes have been redefined in light of this risk progression, with stage 1 now denoting the presence of two or more autoantibodies and stages 2 and 3 indicating the development from abnormal glycemia to overt diabetes, as determined by accepted standards. Defining multiple autoantibody positivity as stage 1 allows for targeted immune interventions and early-life intervention studies, considering the time it may take to progress from islet autoantibody positivity to clinical diabetes.

Genetics Factors

Type 1 Diabetes is a polygenic condition with a genetic component. Siblings of people with type 1 diabetes have a 6% to 7% chance of getting the disease, whereas the concordance rate among identical twins is thought to be between 30% and 70%. A parent with diabetes increases the risk for their children by 1% to 9%. Approximately one in 250 persons have a lifetime chance of developing type 1 diabetes. However, this risk varies between nations and areas of the world. Men and boys are more likely to contract the illness than women and girls. About 50% of the heredity of type 1 diabetes is connected with two particular HLA class 2 haplotypes, HLA DRB10301-DQA10501-DQB10201 (DR3) and HLA DRB10401-DQA10301-DQB10302 (DR4-DQ8), which are often prevalent in white people. It is unclear exactly how these HLA haplotypes affect and change the likelihood of contracting the illness. Other racial groupings have other HLA relationships. However, these are little understood.

Furthermore, more than 60 non-HLA loci are linked to the incidence of type 1 diabetes by genome-wide association studies. These variations emphasize the significance of insulin gene expression in the thymus, control of T-cell activation, and viral responses in the development of the illness and mainly alter immune-related pathways. These genetic relationships, both HLA and non-HLA, offer prospective therapeutic targets and may assist in pinpointing patient subgroups who may benefit from specific immune therapy. HLA or family risk factors have historically been used to identify people with type 1 diabetes at high risk for study. However, type 1 diabetes cannot be predicted or distinguished from other kinds of diabetes using a single non-HLA locus alone. It is possible to identify type 1 diabetes from type 2 diabetes and improve the prediction of type 1 diabetes risk by combining HLA and non-HLA genetic markers into genetic risk scores. Future population-level illness prediction using genetic risk scores may be possible if genotyping costs continue to decrease.



Global and regional diabetes prevalence estimates and projections. This is the Diabetes prevalence by gender and age. Statistics from the International Diabetes Federation Diabetes Atlas.

Epidemiology of Type 1 Diabetes

The incidence and prevalence of type 1 diabetes are rising globally, with a yearly rise of roughly 2-3%. According to data from the United States, there are around 2r, and other areas have also recorded comparable rates. Children under 15 years old, especially those under 5, are shown to have the most significant incidence increases. Genetic alterations alone cannot explain these increases, suggesting that behavioral or environmental variables, or maybe both, are at play. Type 1 diabetes has been linked to several environmental variables, including the food of infants and adults, vitamin D levels, early life exposure to viruses linked to islet inflammation (such as enteroviruses), and decreased diversity in the gut microbiota.

Additionally, obesity is associated with a higher incidence of type 1 diabetes, possibly due to beta-cell stress. The growing occurrence of type 1 diabetes among genetically low-risk people and the significant heterogeneity in type 1 diabetes incidence across genetically similar groups divided by socioeconomic borders highlight the significance of environmental risk factors independent of genetic susceptibility. Understanding gene-environment interactions in the onset of type 1 diabetes, the function of various genetic loci and pathways at different stages of the disease, and whether loci unrelated to disease risk may contribute to disease progression after the onset of autoimmunity are all topics of ongoing research. A probable decrease or stabilization in the incidence of type 1 diabetes in adults has been suggested by specific statistics. Still, more comprehensive data from global registries are required to validate this trend. The prevalence of type 1 diabetes varies between nations and areas within countries. People born in the spring are more likely to develop the condition than those born in other seasons in areas with northern latitudes. Children between the ages of 10 and 14 had the highest diagnosis rate. While many people are diagnosed with type 1 diabetes during adulthood, the higher prevalence of type 2 diabetes in adults and the challenges in accurately distinguishing between the two forms of the disease make it difficult to assess the true incidence of type 1 diabetes in adults. However, it should be noted that most individuals living with type 1 diabetes are adults.

Type 1 Diabetes, Role of B-cell Phenotype

Compared to healthy people, those with type 1 diabetes have beta cells, which produce insulin, that are less functional at the time of diagnosis. However, with better glycemic management, these beta cells might partially regain their ability to secrete insulin. As a result, there may be a honeymoon phase right after diagnosis, during which little to no exogenous insulin is needed. Many of these surviving beta cells are lost over time. Even decades after a person is diagnosed with type 1 diabetes, research looking at pancreatic tissue samples from such individuals has found that there are still some beta cells present. 30-80% of people with long-term type 1 diabetes still secrete some amount of insulin, according to sensitive measures of the insulin secretion marker C-peptide. This shows that while beta cell number and function decrease with the progression of the illness, total beta cell death does not take place. This conclusion is relevant since it was shown that prolonged C-peptide secretion was linked to a decreased risk of developing complications such as retinopathy, nephropathy, and hypoglycemia in the Diabetes Control and Complications Trial. Additionally, leftover C-peptide production may enhance the glucagon responses to hypoglycemia. The prospect of increased efficiency of therapies meant to preserve or boost the survival of these cells is also provided by the presence of these leftover beta cells. Even though the processes underpinning the survival of remaining beta cells in people with long-term type 1 diabetes are not entirely known, figuring out these pathways might offer novel treatment ideas. Beta cell abnormalities, sometimes known as "beta-cell suicide," may also play a role in the onset of type 1 diabetes. It is typical to see increased expression of HLA class I molecules on beta cells in pancreatic tissue from people with type 1 diabetes, which serve as signals for cytotoxic T lymphocytes. It is not yet apparent, though, whether this enhanced expression results from a basic beta-cell dysfunction or a reaction to a stimulus like a viral infection—additionally, data points to the possibility that elevated endoplasmic reticulum stress speeds up beta-cell demise. Stress is linked to mistakes in protein translation and folding, which can lead to the creation of neoantigens that may be immunogenic. In addition to beta-cell deficiencies, anomalies in non-endocrine islet cells and the exocrine pancreas have also been noted. These include vascularity, islet innervation, and anomalies in the extracellular matrix of the islets. As patients with type 1 diabetes have lower pancreatic weight and volume than healthy persons, and as the illness progresses, these dimensions continue to diminish, there is growing acknowledgment of the significance of exocrine pancreatic pathology in the condition. Investigations are currently ongoing to determine the exact reasons for this exocrine pancreatic pathology. However, they may be linked to developmental flaws, pancreatic shrinkage brought on by insulin's lack of paracrine and growth-promoting actions, chronic inflammation, or autoimmune-mediated exocrine pancreas destruction.



Understanding Type 2 Diabetes

High blood sugar levels are used to diagnose diabetes, but several complicated mechanisms might cause this illness. These mechanisms have an impact on how diabetes manifests and develops, as well as how it responds to treatment and how complications form. The autoimmune loss of beta cells that results in type 1 diabetes is a significant distinction between the etiology of diabetes. Pancreatic autoantibodies in the blood are a diagnostic indicator for type 1 diabetes. Other factors contributing to diabetes include genetic flaws that result in monogenic diabetes, including MODY (a type of diabetes that occurs before adolescence).In situations like type 1 diabetes (pancreatic antibodies), hemochromatosis (ferritin, gene sequencing), Cushing's syndrome (dexamethasone suppression test), and MODY (gene sequencing), diagnostic tests can be utilized to identify the precise cause of diabetes. Type 2 diabetes can only be diagnosed by ruling out other potential causes because there is no particular diagnostic test for it. Type 2 diabetes doesn't have a unique diagnostic test, which raises the possibility that there are other subtypes within this category, each with its own diagnostic biomarkers. According to another viewpoint, the lack of essential diagnostic indicators reflects the polygenic character of typically complicated illnesses like type 2 diabetes. Type 2 diabetes may originate from genetic causes, similar to how multiple genes influence height without clear categories. It's important to distinguish type 2 diabetes from other known causes in order to comprehend its complexity. Before examining the various type 2 diabetes subtypes, it's crucial to rule out other diseases. For instance, type 1 diabetes can strike at any age, and the genetic testing for monogenic diabetes varies depending on the area. It is essential to correctly diagnose monogenic diabetes since some people may not need to take insulin. Diagnosis of type 1 and monogenic diabetes can be enhanced by diagnostic procedures that assess C-peptide and pancreatic autoantibodies. Genome-wide association studies have shown frequent genetic variations linked to type 2 diabetes, although these variations only account for a small portion of the disease's heritability. Recent large-scale sequencing studies have demonstrated that whereas common genetic variations greatly contribute to the overall phenotypic variance of type 2 diabetes, uncommon genetic variants have a limited effect. Different levels of diabetes risk can emerge from these frequent variations. Low-frequency variations with significant effects have been found in certain isolated communities, and they can account for a significant amount of the risk of developing diabetes. In these circumstances, the subtype of diabetes may be redefined in light of the genetic etiology. For instance, a particular gene mutation known as TBC1D4 is present in a sizable proportion of the Inuit population and is linked to an increased risk of type 2 diabetes. People with this mutation display distinctive physiological traits such as significant postprandial hyperglycemia. Based on the genetic origin of these particular subtypes, targeted therapies may be created. Type 2 diabetes is a diverse disease with wide phenotypic heterogeneity. In addition to genetics, lifestyle choices, and environmental exposure can affect this variance. According to diabetes "palette model," type 2 diabetes is thought to emerge as a result of flaws in a number of different routes. These routes include fat distribution, glucagon secretion, and action, incretin production and action, insulin action, beta cell activity, and beta cell mass. Different people may have flaws in various combinations of these pathways, which might ultimately result in the development of diabetes. Numerous strategies may be used to comprehend the underlying etiological mechanisms and forecast the diabetes phenotype. Directly measuring physiological processes is one of them, as are utilizing partitioned polygenic scores to estimate genetic contributions, evaluating intermediate phenotypes recorded by metabolomics or proteomics, and merging numerous omics data in an integrated manner.

Biomarkers

The prevalence and incidence of type 2 diabetes (T2D), a health problem affecting the world, are rising quickly. By 2045, it is predicted that there will be 629 million individuals worldwide who have diabetes, up from 425 million in 2017. Early therapies to stop or postpone the onset of T2D depend on the ability to identify people who are at a high risk of acquiring the condition. Insufficiency in pancreatic insulin production and insulin resistance in skeletal muscle and the liver are the two main pathophysiological processes that define T2D. There is rising evidence that genetic

factors significantly influence disease risk, even if the genetic and environmental variables causing T2D are poorly understood. In the genetics of T2D, genome-wide association studies (GWASs) have identified over 400 unique association signals that account for 18% of the risk, making significant findings. Low-frequency genetic variations do not contribute as much to T2D heritability as common genetic variants do. In addition, lifestyle factors, including obesity, inactivity, and poor eating habits, raise the risk of T2D by causing insulin resistance. Understanding T2D and creating focused therapies depend on identifying risk factors and biomarkers for the condition. Numerous risk factors for T2D have been identified in large prospective population-based studies, including the Metabolic Syndrome in Men (METSIM) study, including age, body mass index (BMI), waist circumference, physical inactivity, smoking, poor diet, and high blood pressure. T2D risk has also been linked to biomarkers such as mannose, fatty acids, proinsulin, inflammatory markers, ketone bodies, lipids, and amino acids. Metabolites linked to T2D have been found using metabolomics, which entails a thorough assessment of metabolic alterations. Research has linked the risk of T2D to metabolites such as leucine, alanine, oleic acid, lysophosphatidylcholine C18:0, and creatinine. Short non-coding RNAs called microRNAs (miRNAs), which control gene expression, have also been researched as possible indicators for T2D risk. The effects of several genetic variations have been combined to create genetic risk scores (GRSs), which are used to predict disease susceptibility. Compared to clinical and laboratory risk variables, early GRSs showed little predictive ability, but later GRSs based on a larger number of variations performed better. Prospective investigations have shown links between GRSs and a higher risk of T2D, fasting glycemia, and a reduced ability to secrete insulin. Studies utilizing Mendelian randomization (MR) have been utilized to prove a connection between biomarkers and the risk of T2D. Genetic variations can be instrumental in MR research to demonstrate a causal relationship. For instance, the researchers discovered that the gut microbiota and short-chain fatty acids influence metabolic characteristics and the risk of T2D causally. These strategies, though, have drawbacks. Standardizing data and comparing outcomes across research are difficult tasks for metabolomics investigations. GRSs' therapeutic usefulness is still debatable since non-genetic variables contribute significantly to the risk of T2D. MR studies offer insightful information but are predicated on assumptions that may not always be accurate. To summarize, knowledge of the T2D risk factors and biomarkers is essential for early diagnosis and disease prevention. T2D risk is influenced by various variables, including genetics, lifestyle, and biomarker factors. Ongoing research attempts to enhance risk prediction and provide individualized treatments for this perplexing condition.

Prevention of Type 1 Diabetes

Genetic Factors

According to studies, a genetic predisposition to type 1 diabetes may account for up to 50% of the risk. Identical twin concordance rates range from 25 to 50 percent, while non-identical twin and sibling concordance rates range from 6 to 7 percent, making relatives of T1D patients more likely to get the illness. Combinations of HLA class II alleles have a significant impact on the chance of developing T1D, and the human leukocyte antigen (HLA) complex on chromosome 6p21 plays a significant role in the disease's pathophysiology. Specific haplotypes, such as DR4-DQ8 and DR3-DQ2, are associated with the greatest risk of T1D. HLA is a substantial risk factor for T1D, although only 10% of people are susceptible, indicating that other genes are likely important in the pathophysiology of the illness. There is no distinct inheritance pattern and a diverse genetic foundation for type 1 diabetes. Only around 13% of patients have a first-degree relative with type 1 diabetes, even though the condition tends to run in some families. Depending on which family members have the disease, you may develop type 1 diabetes. 8% for siblings with type 1 diabetes, 3% for the mother, 5% for the father. Her risk is increased if she has several first-degree relatives with type 1 diabetes. Her type 1 diabetes was consistent with just around half of identical twins, indicating environmental and/or epigenetic factors. Nearly 60 loci are associated with susceptibility to type 1 diabetes. Mutations in the HLA region account for about half of the familial inherited risk, while mutations in other genes contribute less to individuals.

Several genetic factors may be important for the emergence of the first islet autoantibodies. This is due to the induction of beta-cell autoimmunity rather than diabetes per se.

The importance of the HLA region on chromosome 6p21 in developing type 1 diabetes. The HLA region is essential to the adaptive immune system and contains over 250 genes, making it the most polymorphic part of the genome. Polymorphism and linkage disequilibrium in the HLA region have made it challenging to identify associations between HLA variants and a first-appearing beta cell autoantibody. HLA class II molecules play a significant role in etiology, pathophysiology, and risk for autoimmune type 1 diabetes. All three HLA-DR, HLA-DQ, and HLA-DP loci have certain variations that can affect a person's likelihood of developing type 1 diabetes and a first beta cell autoantibody. The emergence of a second beta cell autoantibody does not appear to be linked to HLA once the first one has developed. Haplotype DRB103:01-DQA105:01-DQB1*02:01 is the most prevalent one. Further research is necessary to better understand the genetic etiology of type 1 diabetes and potential environmental triggers because of the significance of the HLA Class II region to its pathophysiology and etiology. Spreading of the autoimmunity to other autoantigens is a component of pathogenesis.

Infections

According to a study on the subject, viral infections are frequently examined in connection to type 1 diabetes (T1D), and there are two primary hypotheses: the hygiene theory and the triggering hypothesis. The triggering theory contends that a certain or a combination of infections may induce T1D by killing pancreatic beta cells. In contrast, the hygiene hypothesis contends that infections in early life may guard against T1D. The majority of viral research on T1D has focused on enteroviruses. The article cites the Diabetes Prediction and Prevention (DIPP) study, which demonstrated a relationship between enterovirus infection and the appearance of the first autoantibody. Early serological studies suggested that coxsackie B viruses, especially the CBV4 serotype, may be linked to T1D. However, the role of rubella infection is controversial because an atypical form of T1D without islet autoimmunity is described in congenital rubella syndrome. The article also notes a correlation between respiratory infections and the increased risk of islet autoimmunity in young children, as described in The Environmental Determinants of Diabetes in the Young (TEDDY) study. The incidence of islet autoimmunity peaks between 6 and 9 months, followed by a decline, which is also observed for respiratory infection episodes.



Different cells within our body are associated with Diabetes, both type 1 and 2.

Prevention

Effective primary diabetes preventive techniques must be implemented at a young age because the onset of beta-cell autoimmunity triggers the disease's fast progression. In Europe, including Belgium, Germany, Poland, the United

Kingdom, and Sweden, the POInT study was launched. It is a randomized, placebo-controlled, double-masked primary prevention trial. This trial aimed to determine whether giving children at high genetic risk for T1D daily oral insulin from 4 to 7 months to 36 months of age can lower the incidence of beta-cell autoantibodies and diabetes. The injection of antigens can promote immunological tolerance, which is the basis for this investigation. Although this study shows promise, complete data are not yet accessible, and new data are anticipated in the coming years.

Furthermore, prior research from March 2007 to December 2015 revealed that 7.5 mg/day of oral insulin did not postpone or stop the onset of T1D among relatives of patients with T1D who had autoantibody-positive blood. The T1D-associated virus is being studied for a potential vaccine with support from the Juvenile Diabetes Research Foundation (JDRF). Also being developed are vaccinations that elicit immunological tolerance to beta-cell antigens. Neoepitopes are also being researched as potential substitute antigenic targets for tolerogenic T1D vaccines.

The development of the neonatal immune system, immune system control, and immune system maturation depends on the gut microbiota. The relationship between the early microbiome or its disturbance and the emergence of islet autoantibodies has been examined in several cohorts. Research continues to determine how the variety of gut microbes affects the risk of T1D in children. According to the TEDDY research, patients with islet autoantibodies or T1D had minor alterations in their microbial communities, but no noticeable taxonomic differences were found. However, considerably more genes were implicated in fermentation pathways and the formation of short-chain fatty acid (SCFA) byproducts in the microbiomes of those who acquired islet autoimmunity (T1D). This is significant since several of his SCFA derivatives, such as butyric acid, have been linked to encouraging anti-inflammatory responses, modulating regulatory T-cell activity, and preserving gut epithelial integrity. The study of the microbiome may offer new insights for creating risk-free methods to modify immunological control in newborns and young children, ultimately delaying the onset of type 1 diabetes.



Environmental factors

An autoimmune condition known as type 1 diabetes results in the loss of the pancreatic beta cells that produce insulin. Although the illness can strike anyone at any age, it typically manifests in childhood or adolescence. Geographically, the incidence of type 1 diabetes varies greatly, with Finland having the highest incidence and China having one of the lowest incidences globally. It's interesting to note that the prevalence rates of diabetes among immigrants often resemble those of the local indigenous populations. Environmental variables triggering beta-cell autoimmunity or contributing to the clinical development of type 1 diabetes include viral diseases and dietary components. Rubella viruses and enteroviruses are among the infectious agents undergoing extensive research. However, the link between congenital rubella infection and type 1 diabetes is still up for debate.

Pregnancy-related Coxsackie infection may cause beta-cell autoimmunity in the mother and raise her child's chance of developing type 1 diabetes. The progression of beta-cell autoimmune to type 1 diabetes in a kid with beta-cell autoimmunity has been linked to dietary components like milk. Clinical studies have not yet proven vitamin D effective in preventing type 1 diabetes through regulating the immune system. Similarly, it has been proposed that the anti-inflammatory qualities of n-3 fatty acids affect autoimmune risk. The development of type 1 diabetes in children, however, was not linked to maternal n-3 long-chain heavy acid levels during pregnancy, according to prospective birth cohort research. The following factors make the body require more insulin: B. In people with beta-cell autoimmunity, high blood sugar levels may hasten the development of type 1 diabetes into a clinical condition. Thus, consumption of high-glycemic-index foods and sweets is linked to the development of clinical illness in children with beta-cell autoantibodies but not to the emergence of islet autoimmunity per se. Rapid growth, puberty, trauma, physical inactivity, obesity, and infections are the causes of the clinical onset of diabetes in children with beta-cell autoimmunity. Psychological stress may also increase the likelihood of autoimmunity and type 1 diabetes, possibly through elevated cortisol levels, which may increase insulin resistance and directly regulate the immune system. I have.

Different Therapies

The main goal of type 1 diabetes cure research for more than 30 years has been to alter the immune system's attack on beta cells. Initially, immunosuppressive medications like ciclosporin were used to prevent T-cell activation; however, despite brief decreases in insulin needs, these therapies did not result in long-lasting remission. Since then, several approaches have been investigated, such as antigen-based trials employing the glutamate decarboxylase (GAD) protein, oral or parental insulin, and regulation of T-cell, B-cell, and cytokine responses. However, results have been conflicting, with most studies demonstrating minimal benefit in preventing or treating type 1 diabetes. Nowadays, tailored methods for triggering tolerance are being investigated, such as intradermal dosages of specific proinsulin peptide fragments in people with distinct genetic profiles. Modulation of T-cell and B-cell responses has also been the target of clinical studies conducted during diagnosis. Despite multiple tries, only a few classes of medications have demonstrated efficacy in maintaining C-peptide production in recent-onset type 1 diabetes in placebo-controlled studies. These drugs include monoclonal antibodies targeting the CD20 receptor on B-cells (rituximab), the CD3 receptor on T-cells (teplizumab and otelixizumab), and interventions that block co-stimulatory signals (abatacept and alefacept). Although these medications showed improvements in C-peptide response, none have been able to reach insulin independence or complete phase 3 studies that might be used in clinical settings. Researchers are investigating combinatorial strategies that concurrently target many facets of the immune response to overcome this difficulty. For instance, early investigations have indicated the potential of low-dose anti-thymocyte globulin in conjunction with granulocyte colony-stimulating factor, which is now being researched in clinical trials for type 1 diabetes with a recent start. Another strategy is to get involved early in the illness while there are still more beta cells. Abatacept and teplizumab are being tested in stage 1 and 2 type 1 diabetes trials through the TrialNet Network. Long-term advantages might result from even moderate beta cell function preservation, and early glycemic management improvements could lower the risk of problems. Another potential treatment for type 1 diabetes is the external replacement of beta cells. Although pancreas transplants, frequently done concurrently with kidney transplants, can give insulin independence for several years, their use is restricted by the dangers associated with surgery and the requirement for immunosuppression. Islet transplantation involves injecting donor islets into the liver and has occasionally successfully established insulin independence. Still, the necessity for immunosuppression and the scarcity of donor islets remain obstacles. Islet transplantation is now used to treat people with severe hypoglycemia unawareness to avert potentially fatal hypoglycemia. Research is being done to develop functional and glucose-responsive beta cells by cell therapy utilizing human embryonic stem cells or induced pluripotent stem cells. Although promising, it is still in its early phases and has difficulties scaling up and reproducing successful outcomes from animal research in human trials. Autologous hematopoietic stem-cell transplantation and injection of autologous T-regulatory cells are two other cutting-edge techniques being investigated. Additionally, drugs targeting beta-cell stress responses are being investigated based on

evidence suggesting the active involvement of beta cells in disease pathogenesis. Despite decades of research, a definitive cure for type 1 diabetes has not been achieved. Various immunomodulatory approaches have shown limited success in preserving beta cell function, but none have led to sustained insulin independence or translated into widespread clinical use. Ongoing



The graph constructed above shows the different cells with each disease.

Prevention of Type 2 Diabetes

Prevention of type 2 diabetes based on regulating intestinal flora

To provide a valuable reference for the clinical diagnosis and treatment of diabetes, the features of intestinal flora in individuals with T2DM and methods for preventing and treating T2DM by controlling intestinal flora are discussed. Intestinal flora, sometimes called gut microbiota, are crucial for preserving a healthy immunological and digestive system. Recent studies have shown that an imbalance in gut microbiota may play a role in the emergence of several diseases, including type 2 diabetes (T2DM). Less beneficial and more dangerous bacteria make up the gut bacteria of people with T2DM, which results in an altered composition of gut bacteria. The development of insulin resistance and chronic inflammation, two critical factors in the emergence of T2DM, are thought to be facilitated by this dysbiosis.

Because of excessive intake of salt, sugar, and fat, chronic metabolic disorders like obesity and diabetes are on the rise due to the acceleration of global urbanization and changes in people's lives and eating habits brought on by economic and societal growth. According to the International Diabetes Federation, there were 463 million diabetics worldwide aged 20 to 79 in 2019. China has the most significant number of adults with diabetes (116.4 million), about a quarter of all persons with diabetes. Over 90% of people with diabetes have type 2 diabetes mellitus, making it the most prevalent disease. Therefore, it is crucial to research the pathophysiological causes of T2DM and its efficient prevention and therapy. Metabolic syndrome, known as T2DM, is defined by an absolute or relative lack of insulin secretion and a decline in insulin sensitivity in target organs. The interaction of hereditary and environmental variables causes T2DM. The metabolic abnormalities of fat, protein, water, and electrolytes come next in importance to the disorder's impact on glucose metabolism. The leading causes of T2DM are insulin resistance and islet cell failure. As

the intestinal flora is crucial in controlling metabolism, immunity, inflammation, and other physiological and pathological processes, there is mounting evidence that aberrant intestinal flora is intimately linked to the onset and progression of T2DM.

Around 1014 different types of bacteria live in the human gut, which is more than 1,000 times the number of human cells. These microorganisms' makeup roughly 80% of the germs in the human body and can weigh up to 1.2 kg in total. Actinomycetes, Proteobacteria, and Verrucomicrobia, are three significant phyla after Bacteroidetes and Firmicutes. Intestinal flora can be categorized as commensal bacteria, opportunistic pathogens, and dangerous bacteria, depending on how they interact with the host. These organisms are mutually reliant and constrained in their physiological states, maintaining a dynamic equilibrium with the human body. Commensals are a part of the body's natural defensive system that keeps humans healthy. Numerous illnesses develop when pathogenic causes disrupt this equilibrium. Numerous studies that examined how type 2 diabetics (T2DM) may have changed gut flora are included in the article. According to specific research, individuals with T2DM had lower levels of specific bacterial species than healthy individuals, including those that produce butyric acid, Faecalibacterium prausnitzii, and Akkermansia muciniphila. The concentrations of other bacterial species, such as Lactobacillus and Streptococcus mutans, are more significant in T2DM patients.

Additionally, several studies have found a clear correlation between blood glucose levels and the ratio of Bacteroidetes to Firmicutes. This ratio has been suggested as a potential T2DM marker by several researchers. According to several studies, the gut microbiota composition of patients with prediabetes differs from that of healthy people and people with T2DM. The study also examines potential mechanisms underlying the association between gut microbiota and type 2 diabetes. For instance, some research has proposed that variations in the gut microbiota's composition may lead to adjustments in the production of short-chain fatty acids, which may impact glucose homeostasis.

Treatments

Treatments using Probiotics and Prebiotics

Probiotics are bacteria that enhance the host's microbiota and positively impact the host's health. Probiotics come in three primary categories: facultative anaerobic cocci, Lactobacillus, and Bifidobacterium. In addition to aiding in digestion and absorption, probiotics also strengthen immune cells, protect the intestinal mucosa, lower the risk of cancer, decrease cholesterol absorption, boost oxidation resistance, and ease constipation. Prebiotics are dietary ingredients that cannot be digested or are challenging to digest. These ingredients specifically boost the colon's bacterial population and activity. Probiotics are essential for protecting against infections, controlling immunological responses, enhancing gut health, promoting mineral absorption, regulating metabolism, preventing hunger, etc. Studies have demonstrated the ability of prebiotics and probiotics to alter the gut flora, increase the relative abundance of Bifidobacterium and Lactobacillus, and enhance lipid and glucose metabolism.

According to research, people with type 2 diabetes who consume a daily milkshake that contains fructooligosaccharides, bifidobacteria, and lactobacillus acidophilus have significantly lower blood glucose levels. Prebiotic vitamins for diabetic pregnant women decreased blood sugar levels throughout pregnancy and 12 months after birth. They also reduced insulin concentrations and increased insulin sensitivity. Probiotic supplementation with WBF-011 can dramatically lower postprandial blood glucose, HbA1c, and total glucose area under the curve, according to a 12-week intervention in type 2 diabetes patients. Short-term or long-term probiotic usage significantly decreased fasting blood glucose, HbA1c, and total serum cholesterol, according to a randomized controlled study in individuals with prediabetes or type 2 diabetes. It is hypothesized that proper probiotic administration can successfully prevent type 2 diabetes from occurring and developing.

Dietary factors

Weight gain and abnormal visceral fat buildup are the leading causes of type 2 diabetes mellitus (T2DM), which can result in metabolic syndrome and other problems. Dietary treatment is a more effective way to treat obesity than pharmacological therapy, and it can stop the condition in its earliest stages. By blocking the action of enzymes involved in glucose metabolism, promoting insulin secretion, regulating hepatic glucose, and reducing hyperglycemia caused by oxidative stress and inflammation, a diet high in dietary polyphenols can help prevent T2DM. Additionally, it can enhance gut flora, which has been associated with improved blood sugar control. Increased fruit consumption has been linked to decreased T2DM risk, mediated by specific intestinal flora and metabolites and the formation of short-chain fatty acids, which boost glucagon-like peptide-1 release and block stomach emptying to reduce hunger. Mushroom polysaccharides can help control intestinal flora and act as an antidiabetic by growing glucagon-like peptide-1 production. As a result, developing healthy eating habits, such as increasing the consumption of fruits and vegetables, can significantly affect the prevention and treatment of T2DM.

Antidiabetic drugs

Recent research has demonstrated that several hypoglycemic medications, particularly metformin, can alter and enhance the gut microbiota in people with type 2 diabetes (T2DM). Patients with T2DM have been demonstrated to have an increased prevalence of bacteria that produce short-chain fatty acids (SCFAs), making metformin the preferred oral medication for lowering blood glucose levels in those with T2DM—research by Sun et al. Metformin was used to treat newly diagnosed T2DM patients, and they discovered significant alterations in the gut microbiota's makeup. The medicine for high-risk groups with the most extensive research to date is metformin. He nonetheless demonstrated a substantial reduction in T2DM incidence after ten years (18% increase compared to placebo), even if metformin was less effective than lifestyle treatments. This discovery suggests that metformin may benefit people with diabetes in ways other than simply managing their early-stage conditions. Advantages that last after the therapy has ended. Metformin was less effective in elderly, nonobese groups and more beneficial in pregnant women with gestational diabetes and younger, obese populations. Lower levels of low-density lipoproteins, triglycerides, and fasting blood sugar are other advantages of metformin that have been well-documented—moderate decrease in weight. as well as increased amounts of HDL cholesterol.

Acarbose and voglibose are two more medications that may lessen the consequences of T2DM; however, acarbose's effectiveness has only sometimes been seen. Thiazolidinediones like pioglitazone can decrease T2DM incidence. However, they can have adverse effects, including weight gain and fluid retention. However, they are the standard of therapy. Dipeptidyl peptidase-4 inhibitors and glucagon-like peptide-1 agonists have been demonstrated to have some effect on the gastrointestinal glucose axis of incretins and may lower the risk of T2DM. There needs to be more data to support this. Orlistat, phentermine-topiramate, and bariatric surgery have all been demonstrated to be beneficial in avoiding his T2DM, a primary therapy objective for most chronic conditions.

Conclusion

In conclusion, patients and healthcare professionals must comprehend and manage type 1 and type 2 diabetes. To prevent catastrophic problems, type 1 diabetes, characterized by the death of pancreatic beta cells, must be strictly controlled with daily insulin injections, blood glucose tests, dietary adjustments, and lifestyle changes. Due to social, emotional, and economic considerations, managing type 1 diabetes can be particularly difficult for teenagers and young adults, including university students. Contrarily, type 2 diabetes, which is impacted by hereditary and environmental factors, necessitates a multifaceted strategy involving lifestyle changes like a healthy diet and frequent exercise, as well as medicine or insulin therapy in certain situations. The necessity of early identification, risk assessment,

and targeted therapies is emphasized by the increased incidence and prevalence of both forms of diabetes worldwide. The title of those at high risk of acquiring type 2 diabetes and the personalization of preventive measures show promise for biomarkers and genetic risk scores. To lessen the burden of diabetes globally, further study is required to comprehend the underlying mechanisms better, enhance diagnostic techniques, and create more efficient therapies.

Acknowledgment

I sincerely thank Coach Jo, a teacher from my old school, and Dr. Rajagopal Appavu for their help and advice during the study process. My high school teacher contributed to igniting my interest in the subject of conducting research. My critical thinking and problem-solving skills have improved thanks to Coach Jo's unrelenting passion and commitment, and he has also taught me the value of perseverance and strenuous effort. She helped me get the fundamental know-how and abilities necessary to conduct research effectively, and she fostered in me a passion for studying that has seen me through my academic endeavors. Lastly, but not least, I sincerely thank Dr. Rajagopal Appavu, who served as my research mentor and gave me crucial advice and assistance during the project. Dr. Appavu's knowledge and insights greatly influenced my study methods and analysis, and his support and mentoring gave me self-assurance and drove me to achieve my research objectives.

References

Acharjee, S., Ghosh, B., Al-Dhubiab, E., & Nair, A. B. (2013, August 2). Understanding type 1 diabetes: Etiology and Models. Canadian Journal of Diabetes. https://pubmed.ncbi.nlm.nih.gov/24070892

Crandall, J. P., Knowler, W. C., Kahn, S. E., Marrero, D., Florez, J. C., Bray, G. A., Haffner, S. M., Hoskin, M., & Nathan, D. M. (2008, July 4). The prevention of type 2 diabetes. Nature Clinical Practice. Endocrinology & Metabolism. https://pubmed.ncbi.nlm.nih.gov/18493227/

DiMeglio, L. A., Evans-Molina, C., & Oram, R. A. (2018, June 16). Type 1 diabetes. Lancet (London, England). https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6661119/

Laakso, M. (2019, September). Biomarkers for type 2 diabetes. Molecular Metabolism. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6768493/

Li, W.-Z., Stirling, K., Yang, J.-J., & Zhang, L. (2020, July 15). Gut microbiota and diabetes: From correlation to causality and mechanism. World Journal of Diabetes. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7415231/

Ling, C., & Ronn, T. (2019, May 7). Epigenetics in human obesity and type 2 diabetes. Cell Metabolism. https://pubmed.ncbi.nlm.nih.gov/30982733/

Meigs, J. B. (2019, July 22). The genetic epidemiology of type 2 diabetes: Opportunities for Health Translation. Current Diabetes Reports. https://pubmed.ncbi.nlm.nih.gov/31332628/

Pearson, E. R. (2019, June 3). Type 2 diabetes: A multifaceted disease. Diabetologia. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6560016/

Regnell, S. E., & Lernmark, A. (2017, August). Early prediction of autoimmune (type 1) diabetes. Diabetologia. https://pubmed.ncbi.nlm.nih.gov/28550517/

Shubrook, J. H., Chen, W., & Lim, A. (2018, November 1). Evidence for the prevention of type 2 diabetes mellitus. De Gruyter. https://www.degruyter.com/document/doi/10.7556/jaoa.2018.158/html

Todd, J. A. (2010, April 23). Etiology of type 1 diabetes. Immunity. https://pubmed.ncbi.nlm.nih.gov/20412756/

Xie, D., Zhao, X., & Chen, M. (2021a, September 26). Prevention and treatment strategies for type 2 diabetes based on regulating intestinal flora. Bioscience Trends. https://pubmed.ncbi.nlm.nih.gov/34565781/

Xie, D., Zhao, X., & Chen, M. (2021, November 21). Prevention and treatment strategies for type 2 diabetes based on regulating intestinal flora. BioScience Trends. https://www.jstage.jst.go.jp/article/bst/15/5/15_2021.01275/_article